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Diabetes mellitus (DM) alters circulating progenitor cells relevant for the pathophysiology of coronary artery disease (CAD).
While endothelial progenitor cells (EPCs) are reduced, there is no data on procalciﬁc polarization of circulating progenitors,
which may contribute to vascular calciﬁcation in these patients. In a cohort of 107 subjects with and without DM and CAD, we
analyzed the pro-calciﬁc versus endothelial diﬀerentiation status of circulating CD34+ progenitor cells. Endothelial commitment
was determined by expression of VEGFR-2 (KDR) and pro-calciﬁc polarization by expression of osteocalcin (OC) and bone
alkaline phosphatase (BAP). We found that DM patients had signiﬁcantly higher expression of OC and BAP on circulating CD34+
cells than control subjects, especially in the presence of CAD. In patients with DM and CAD, the ratio of OC/KDR, BAP/KDR,
and OC+BAP/KDR was about 3-fold increased than in other groups. EPCs cultured from DM patients with CAD occasionally
formed structures highly suggestive of calciﬁed nodules, and the expression of osteogenic markers by EPCs from control subjects
was signiﬁcantly increased in response to the toll-like receptor agonist LPS. In conclusion, circulating progenitor cells of diabetic
patients show a phenotypic drift toward a pro-calciﬁc phenotype that may be driven by inﬂammatory signals.
1.Introduction
Diabetes mellitus (DM) is associated with an excess risk of
cardiovascular disease, which is attributable to hyperglyce-
mia,oxidativestress,andinﬂammation[1].Inparallel,repair
of vascular damage is compromised in DM owing to a pau-
perization of circulating endothelial progenitor cells (EPCs)
[2]. In the bloodstream, other lineage-committed progen-
itor cells may have pathophysiological implications in the
cardiovascular system, such as smooth muscle and cardi-
omyocyte progenitors [3, 4]. DM reduces circulating EPC
level [5] and is also associated with an impaired generation
of EPCs paralleled by enhanced diﬀerentiation of smooth
muscle progenitors in vitro [6, 7]. A drift of circulating pro-
genitors from the endothelial to smooth muscle-cell phe-
notype has been linked to the development of myointimal
hyperplasia [8], an event that is associated with diabetes. The
impaireddiﬀerentiationofculturedEPCsindiabeticpatients
has been previously attributed to a proinﬂammatory status
[9]. EPCs promote endothelial healing and compensatory
angiogenesis, thus providing a mean of vascular repair [10].
Therefore, abnormalities of progenitor cells are considered
important contributors to the development of diabetic vas-
culopathy, which is characterized by extensive endothe-
lial dysfunction/damage and myointimal hyperplasia [11].
Another hallmark feature of diabetic vasculopathy is ectopic
calciﬁcation. Intimal microcalciﬁcations of atherosclerotic
lesions contribute to destabilize the plaque, while medial
calciﬁcation rises arterial stiﬀness and blood pressure [12,
13]. The mechanisms increasing vascular calciﬁcation in dia-
betes are incompletely understood, but cell-mediated pro-
cesses are increasingly studied. In 2005 Eghbali-Fatourechi
and coworkers described the existence of osteoblastic cells in
thehumanperipheralblood[14],suggestingfortheﬁrsttime2 Experimental Diabetes Research
that circulating cells may contribute to ectopic calciﬁcation.
This hypothesis has been supported by the discovery of
myeloid calcifying cells (MCCs) and by evidence of a poten-
tial role for circulating cells in vascular and valve calciﬁca-
tion [15–17].
Based on this background, we hypothesize that circu-
lating progenitor cells of diabetic patients may undergo a
phenotypic shift from the protective endothelial commit-
ment to a detrimental pro-calciﬁc phenotype. To test this
hypothesis, we analyzed expression of endothelial and osteo-
genic markers on circulating CD34+ cells and evaluated pro-
calciﬁc diﬀerentiation of EPCs in vitro.
2.MaterialsandMethods
2.1. Patients. The study was approved by the Ethical Com-
mittee for Clinical Experimentation of the University Hos-
pital of Padova. Type 2 diabetic patients and controls were
recruited at the outpatient clinics of the Division of Meta-
bolic Diseases. The same exclusion criteria applied to all
patients: age <18 or >80 years; recent (within 1 month)
trauma, surgery, or revascularization; immunological dis-
ease, immunosuppression, or cancer; any acute disease or
infection; pregnancy and lactation. Patients were divided
according to the presence of diabetes mellitus (DM) and
coronary artery disease (CAD). Type 2 DM was diagnosed
according to American Diabetes Association criteria [18].
CAD was deﬁned in the presence of at least one of the
followings: a past documented history of myocardial infarc-
tion; angiographic evidence of one or more >70% stenosis of
epicardial coronary arteries; evidence of inducible ischemia
from a noninvasive stress test (either single-photon emis-
sion tomography or ultrasound Doppler examination). All
patients were characterized by collection of the following
data: age, sex body mass index (kg/m2), systolic and diastolic
blood pressure, diagnosis of hypertension, history of smok-
ing, fasting plasma glucose, glycated hemoglobin (HbA1c),
total cholesterol, HDL cholesterol, and triglycerides concen-
tration. We also recorded data on diabetic complications,
included retinopathy (deﬁned by the ETDRS classiﬁcation
[19]), neuropathy (deﬁned by suggestive symptoms and
signs, eventually conﬁrmed by an electromyogram), and
nephropathy (deﬁned as either a urinary albumin excretion
rate >30mg/g creatinine or an estimated glomerular ﬁltra-
tion rate [eGFR, according to the MDRD equation [20]]
<60mL/min/m2). Peripheral arterial disease was deﬁned
as a history of claudication or rest pain in the presence
of a signiﬁcant stenosis of leg arteries on an ultrasound
or angiographic examination. Cerebrovascular disease was
deﬁned as either a history of past stroke/transient ischemic
attack, or evidence of carotid atherosclerotic plaques, deter-
mining a stenosis >20% of vessel lumen, on an ultrasound
examination. Finally, we also collected data on medications.
2.2. Cell Culture. Late outgrown EPCs were cultured from
peripheral blood mononuclear cells as previously described
[6]. Brieﬂy, cells were plated on six-well ﬁbronectin-coated
plates at a density of 6 ×106 cells per well and grown in sup-
plemented endothelial cell growth medium (Clonetics) with
20% serum. The medium was changed the ﬁrst time after 4
days and then each other day for a total of 2 weeks. We have
previously shown that during the culture protocol these cells
formclusterswithacoremadeofroundedcellsandradiating
spindle-shaped cells at the periphery. At 12–14 days, these
clusters dissolve and cells progressively develop as a mono-
layer. We characterized these cells by double immunoﬂuo-
rescence; cells were incubated at 37◦C with 1mg/mL Di-
I-AcLDL (DiIacetylated low-density lipoproteins, Molecular
Probes) for 1h, followed by dark incubation with 15mg/mL
FITC-conjugated Ulex lectin (Sigma-Aldrich) for 2h. Nuclei
were stained in blue with Hoechst 33258 (Sigma-Aldrich). In
separated experiments, cells were cultured in the presence of
LPS(Sigma-Aldrich)fromday7to14ataﬁnalconcentration
of 100nM; untreated cells served as controls, and expression
level was set at 1. In parallel we also cultured human umbili-
cal vein endothelial cells (HUVECs, Clonetics) and analyzed
the expression of bone-related markers in untreated and
LPS-treated cells. Experiments were performed in triplicate.
Alizarin red and von Kossa stainings were not performed.
2.3. Flow Cytometry. Expression of progenitor cell antigens
and diﬀerentiation markers was analyzed by multicolor ﬂow
cytometry on fresh whole peripheral blood samples. Brieﬂy,
after red blood cell lysis, cells were incubated with speciﬁc
monoclonal antibodies anti-CD34 (-PE or -FITC conju-
gated, Becton Dickinson, BD), PE-conjugated anti-KDR
(R&D Systems), or PE-conjugated anti-OC (R&D Systems)
and APC-conjugated anti-BAP (R&D Systems). OC/BAP
costaining with KDR was not performed. After washing, cells
were analyzed by FACSCalibur instrumentation (BD) set up
for analysis or rare events. We ﬁrst gated CD34+ cells in the
mononuclear cell fraction and then examined the resulting
population for dual expression of KDR or dual/triple
expression of OC and/or BAP. At least 5 × 105 events were
acquired, and positive events were recorded as a fraction
of the number of fated CD34+ cells. All analyses were per-
formed by trained operators blinded to the patients status.
For the analysis of cell culture, a similar gating strategy
was used, with the same directly labelled monoclonal anti-
bodies plus the PE-conjugated anti-RANKL mAb.
2.4. Statistical Analysis. Data are expressed as mean and
standard error or as percentage, where appropriate. Com-
parison between 2 or more groups was performed using
Student’s t test or ANOVA, respectively. The Least Signiﬁ-
cance Diﬀerence (LSD) post hoc test was used. Comparison
of categorical data was tested using the Chi square test.
To test the independent association of the coexistence of
DM and CAD on progenitor cell phenotypes, we run a
multiple linear regression analysis in which DM+CAD+
was an independent variable together with other covariates.
Covariates were selected for being diﬀerent at P<0.05 at the
univariate comparison between patients with and without
DM and CAD. Statistical signiﬁcance was accepted at P<
0.05, and the SPSS versus 16.0 was used.Experimental Diabetes Research 3
Table 1: Clinical characteristics of study patients divided according to the presence of DM and CAD. Post hoc analyses: ∗P<0.05 in DM+
versus DM−; #P<0.05 in CAD+ versus CAD−.
Characteristic DM−CAD− DM−CAD+ DM+CAD− DM+CAD+ ANOVA P
Number 33 19 33 22 —
Age (years) 54.3 ±3.25 2 .4 ±3.16 1 .9 ±1.8∗ 67.3 ±1.4∗ <0.001
Sex male (%) 38 79# 70∗ 86 0.001
BMI (kg/m2)2 4 .8 ±0.42 6 .8 ±1.32 8 .3 ±0.9∗ 30.6 ±0.9∗ <0.001
SBP (mmHg) 139.1 ±4.1 120.4 ±5.6 143.2 ±3.2 141.7 ±4.8 <0.001
DBP (mmHg) 83.4 ±2.37 5 .3 ±2.18 5 .9 ±2.18 4 .5 ± 2.1 <0.001
Hypertension (%) 30 32 88∗ 91∗ <0.001
Smoking habit (%) 16 26 6 5 0.102
HbA1c (%) 5.2 ±0.25 .8 ±0.18 .4 ±0.3∗ 8.1 ±0.3∗ <0.001
FPG (mg/dL) 87.9 ±3.99 9 .3 ±4.9 164.3 ±11.6∗ 161.4 ±10.5∗ <0.001
T-CH (mg/dL) 203.1 ±7.1 183.6 ±11.6 178.9 ±6.4∗ 158.5 ±7.9∗ 0.002
HDL (mg/dL) 60.0 ±3.74 9 .2 ±1.9# 48.1 ±2.1∗ 39.6 ±2.0#∗ <0.001
LDL (mg/dL) 125.2 ±6.7 105.7 ±11.3 100.1 ±5.6∗ 90.8 ± 6.5 0.008
Triglycerides (mg/dL) 94.7 ±7.9 144.3 ±27.9 150.4 ±17.3∗ 141.0 ±12.4∗ 0.056
Retinopathy (%) 0 0 21∗ 36∗ <0.001
Nephropathy (%) 0 16 6 27#∗ 0.07
Neuropathy (%) 0 0 21∗ 27∗ 0.02
CerVD (%) 21 5 70∗ 50∗ <0.001
PAD (%) 6 0 42∗ 32∗ <0.001
OHA (%) 0 0 76∗ 68∗ <0.001
Insulin (%) 0 0 42∗ 41∗ <0.001
ACEi/ARB (%) 28 95# 76∗ 77 <0.001
Other anti-HT (%) 22 84# 55∗ 77 <0.001
Aspirin (%) 16 79# 76∗ 86 <0.001
Statin (%) 19 68# 58∗ 86 <0.001
BMI: body mass index. SDP, systolic blood pressure. DBP: diastolic blood pressure. FPG: fasting plasma glucose. T-CH: total cholesterol. HDL: high-
density lipoprotein cholesterol. LDL: low density lipoprotein cholesterol. CerVD, cerebrovascular disease. PAD: peripheral arterial disease. OHA: oral
antihyperglycemic drugs. ACEi: angiotensin conerting enzyme inhibitors. ARB: angiotensin receptor blockers. AntiHT, anti-hypertensive medications.
3. Results
3.1. Patients’ Characteristics. A total of 107 subjects were in-
cluded in the study. They were divided into 4 groups accord-
ing to the presence of DM and/or CAD. Sample size was
fairly balanced among groups. Among patients without DM,
patients with CAD had a higher prevalence of the male gen-
der, lower HDL cholesterol, and a much larger use of cardio-
vascular medications than in those without. Obvious dif-
ferences were detected in patients with DM than in those
without, including older age, prevalence of males, higher
BMI,bloodpressure,cholesterol,plasmaglucoseandHbA1c,
comorbidities, and medications. Interestingly, among DM
patients, the presence of CAD was only associated to a sig-
niﬁcantly lower HDL cholesterol and higher prevalence of
nephropathy (Table 1).
3.2. Expression of Bone-Related Markers on Circulating Pro-
genitor Cells. To detect the pro-calciﬁc diﬀerentiation of cir-
culating CD34+ progenitor cells, we analyzed the expression
ofOCandBAP.InCD34+ cellsfromcontrolhealthysubjects
(DM−CAD−), OC was expressed on 26.7±2.1% while BAP
wasexpressedon20.8±1.7%ofcells,andthecoexpressionof
both markers was 12.9±1.4%. The expression of OC and/or
BAP was signiﬁcantly increased in patients with DM and/or
CAD. Speciﬁcally, OC expression was higher in CAD versus
non-CAD patients independently of DM, and in DM versus
non-DM patients independently of CAD. BAP expression
was higher in DM versus non-DM patients, especially in the
presence of CAD. Co-expression of OC and BAP on CD34+
cells was signiﬁcantly higher in both DM and CAD patients
(Figures 1(a), 1(b),a n d1(c)).
3.3. Procalciﬁc Phenotypic Drift of Circulating Progenitors. In
parallel to the analysis of bone-related markers, we also ex-
amined the extent to which circulating CD34+ progeni-
tor cells express the endothelial antigen KDR, which func-
tionally represents type 2 VEGF receptor and is usually
taken to represent endothelial diﬀerentiation [21]. This was
used to determine the ratio of bone versus endothelial
mark-er expression on CD34+ cells, as an indicator of a
phenotypic drift of circulating progenitors toward the pro-
calciﬁc phenotype. We found that OC/KDR, BAP/KDR,
and OC+BAP/KDR expression ratio was increased in
DM+CAD+ patients versus controls by 3.6-, 2.9-, and 3.0-
fold, respectively, while there were no diﬀerences among4 Experimental Diabetes Research
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Figure 1:Expressionofbone-relatedmarkersoncirculatingCD34+progenitorcells.Patientsweredividedaccordingtothepresence/absence
of type 2 diabetes mellitus (DM) and coronary artery disease (CAD). Post hoc tests: ∗P<0.0 5i nD M +v e r s u sD M −; #P<0.05 in CAD+
versus CAD−.
other groups (Figures 1(d), 1(c), 1(e),a n d1(f)). Upon a
multipleregressionanalysis,thecoexistenceofDMandCAD
remained signiﬁcantly associated with increased OC/KDR,
BAP/KDR, and OC+BAP/KDR expression ratio versus other
patients, independently of age, prevalence of hypertension,
concentrations of total cholesterol, HDL and LDL, which
were signiﬁcantly diﬀerent between the two groups (Delta ±
SE 16.7±6.1 for OC/KDR, P = 0.08; 8.7±4.0 for BAP/KDR,
P = 0.030; 6.8 ± 2.9 for OC+BAP/KDR, P = 0.023).
3.4. Calciﬁcation and Expression of Bone-Related Markers in
Cultured EPCs. To assess whether endothelial progenitors
cultured from peripheral blood mononuclear cells can
undergo a pro-calciﬁc diﬀerentiation, we isolated late EPCs
from diabetic patients. Extensive characterization of these
c e l l si sr e p o r t e de l s e w h e r e[ 6, 22]. Clusters of EPCs occa-
sionally formed dense nodules that were highly suggestive of
calciﬁcation only when cultured from DM+CAD+ patients
and not from DM+CAD− patients (2/6 versus 0/7, P = 0.05,
Figure 2(a)). As EPCs express the LPS receptors CD14 and
toll-likereceptor-2(TLR-2)[23],wetestedwhetherchalleng-
ing EPCs isolated from DM-CAD subjects with LPS resulted
in upregulation of bone-related markers. We found that LPS
signiﬁcantlyincreased2.6-foldOC+BAP+cellsintheculture
and upregulated BAP (3.0-fold) and RANKL (5.8-fold) on
CD34+cells.InHUVECs,whichservedasacontrolcelltype,
there were similar increases in OC+BAP+ cells (2.6-fold),
and expression of BAP (2.9-fold), but there was no change
in expression of the osteoblast marker RANKL (Figure 2(b)).
4. Discussion
In the present study, we demonstrate for the ﬁrst time
that circulating progenitor cells from diabetic patients with
coronary artery disease undergo a pro-calciﬁc phenotypic
shift, as evidenced by increased expression of bone-related
markers versus endothelial markers.
In recent years, evidence accumulated in support of
the existence of circulating progenitors for several lineages
important for the cardiovascular system, including endothe-
lial (EPCs), smooth muscle, and cardiomyocyte progenitor
cells [3, 4, 24]. EPCs are by far the most extensively char-
acterized of these circulating progenitors; they are deﬁned
by co-expression of immaturity (e.g., CD34) and endothelial
(e.g., KDR) antigens [25]. About 10–15% of circulating
CD34+ express KDR, the %KDR expression is usually taken
to represent the extent to which circulating progenitors are
committed to the endothelial lineage [21]. Recent data have
demonstrated that circulating CD34+ progenitor cells and
CD34+KDR+ EPCs can also express bone-related proteins,
especially OC [26, 27]. Several preclinical studies and
preliminary clinical evidence indicate that EPCs home to
sites of vascular damage [28, 29]. Therefore, an osteogenic
diﬀerentiation of these cells may be involved in the process
of vascular calciﬁcation. G¨ ossl et al. have found that OC
expression on circulating EPCs is signiﬁcantly associated
with CAD in a cohort of patients with a very low prevalence
of diabetes (7/72, 10%) [27].
Subsequently, they have demonstrated that OC-
expressing EPCs are retained in the coronary circulation ofExperimental Diabetes Research 5
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Figure 2: Pro-calciﬁc diﬀerentiation of cultured EPCs. (a) EPCs cultured from DM+CAD+ patients developed dense nodules highly
suggestive of calciﬁcation, while EPCs cultured from DM+CAD− patients did not. The lower lane shows double Lectin/AcLDL
immunoﬂuorescence analysis of cultured EPCs. ((b) and (c)) Cultured EPCs and HUVECs express bone-related antigenic markers after
challenging with LPS 100nM for 7 days. ∗P<0.05 versus control experiment, set at 1.0.
patientswithcoronaryendothelialdysfunction,providingan
indirect evidence in support of homing of these pro-calciﬁc
cells at sites of vascular damage [26]. We have previously
shown that OC+BAP+ myeloid calcifying cells (MCCs) are
increased in the bloodstream and in calciﬁed atherosclerotic
lesions of type 2 diabetic patients [15], providing the ﬁrst
evidence that circulating cells may contribute to ectopic
vascular calciﬁcation. However, so far, there was no data on
pro-calciﬁc diﬀerentiation of circulating progenitor cells in
diabetic patients. This is of paramount importance because
diabetes is typically associated with an exceedingly high
prevalence of vascular calciﬁcation, either medial or intimal6 Experimental Diabetes Research
[30]. Herein, we show that expression of OC and BAP on
CD34+ cells is increased in patients with either DM or CAD
and that the coexistence of DM and CAD is associated with
an almost doubled expression of these bone-related proteins.
OC is a noncollagenous bone protein implicated in bone
mineralization and calcium homeostasis, while BAP is a
tetrameric glycoprotein found on the surface of osteoblast
cells, and its function is essential to the mineralization pro-
cess. If these cells are recruited to sites of vascular damage,
it is easy to anticipate how they may promote the process
of vascular calciﬁcation. Importantly, we have previously
shown that the expression of KDR on CD34+ cells is reduced
in diabetic patients with macroangiopathy, indicative of
an impaired endothelial diﬀerentiation and generation of
EPCs. Together with the enhanced osteogenic polarization,
data consistently suggest that circulating progenitor cells
of diabetic patients undergo a phenotypic drift toward the
detrimental osteogenic phenotype at the expenses of the
vasculoprotective endothelial phenotype. To quantitatively
support this hypothesis, we examined the expression ratio of
bone-related markers OC and BAP over KDR on circulating
CD34+ cells. We found that OC/KDR, BAP/KDR, and
OC+BAP/KDR are markedly elevated only in patients with
DM and CAD and not in patients with either conditions,
strengthening the association between this pro-calciﬁc drift
and diabetic vascular disease.
T h ed e g r e eo fp r o - c a l c i ﬁ cd i ﬀerentiation of CD34+ cells
resembles the extent of OC and BAP expression on circulat-
ing monocytes and the levels of MCCs [15], suggesting that
the driving force of the osteogenic program acts similarly
on diﬀerent cellular populations. To study the pro-calciﬁc
polarization of progenitor cells in vitro, we cultured late out-
grown EPCs and found that they formed hyperdense
nodular structures, highly suggestive of calciﬁcations, only
in DM+CAD+ patients and not in DM+CAD− patients.
We hypothesized that EPC calciﬁcation may be driven by
chronic inﬂammation through stimulation of innate im-
munityreceptors,suchasCD14andTRLs[23,31,32],which
are expressed by EPCs. Indeed, this pathway has been pre-
viously shown to be overactivated in diabetic patients and
cardiovascular disease [33]. When EPCs were isolated from
DM−CAD− patients and cultured with or without the TRL
ligand LPS, expression of bone-related markers was signiﬁ-
cantly upregulated, also in co-expression with CD34. Of
note, OC and BAP overexpression was found also in
HUVECs in response to LPS, indicating that this phenotypic
change occurs in endothelial cells independently of their ori-
gin. This ﬁnding should be viewed in light of the postulated
cross-talk between endothelial cells and osteoblasts in the
regulation of bone turnover [34]. Remarkably, induction of
the osteoblast marker RANKL by LPS occurred only in EPCs
and not in HUVECs, supporting that EPCs have a strong-
er tendency toward the osteogenic phenotype. It should be
carefully noted that we did not deﬁnitely prove that EPC
calciﬁed in vitro. While it may be surprising that these cells
spontaneously deposit calcium in culture without osteo-
genic stimuli, the relatively high serum concentration used
for EPC isolation (20%) may represent a source of calci-
um/phosphate. Our data are supported by the recent ﬁnding
of Liu et al. showing that oxidized low-density lipoprotein
and β-glycerophosphate induce extensive EPC calciﬁcation
invitro[35].However,furtherstudiesareneededtodeﬁnein
greater detail the calciﬁcation potential of EPCs in diﬀerent
culture conditions and in vivo.
5. Conclusion
Our data have important implications for the interpretation
ofcirculatingprogenitorcellphenotypeinrelationtocardio-
vascular complications of diabetes. Reduced progenitor cell
level and impaired endothelial diﬀerentiation are currently
considered mechanisms whereby diabetes causes endothelial
dysfunction and excess vascular damage [11]. Our present
data indicating pro-calciﬁc diﬀerentiation of circulating
progenitors add a new plug to the puzzle and identify a hith-
erto unrecognized potential mechanism of vascular calcif-
ication in diabetes.
Acknowledgment
This study was supported by a European Foundation for the
StudyofDiabetes(EFSD)YoungInvestigatorAwardGrantto
G. Paolo Fadini.
References
[1] A. Avogaro, S. V. D. Kreutzenberg, and G. Fadini, “Endothelial
dysfunction: causes and consequences in patients with dia-
betes mellitus,” Diabetes Research and Clinical Practice, vol. 82,
supplement 2, pp. S94–S101, 2008.
[ 2 ]A .A v o g a r o ,M .A l b i e r o ,L .M e n e g a z z o ,S .D eK r e u t z e n b e r g ,
and G. P. Fadini, “Endothelial dysfunction in diabetes: the role
ofreparatorymechanisms,”DiabetesCare,vol.34,supplement
2, pp. S285–S290, 2011.
[3] M. Albiero, L. Menegazzo, and G. P. Fadini, “Circulating
smooth muscle progenitors and atherosclerosis,” Trends in
Cardiovascular Medicine, vol. 20, no. 4, pp. 133–140, 2010.
[4] W. Wojakowski, M. Tendera, A. Michałowska et al., “Mobi-
lization of CD34/CXCR4+, CD34/CD117+,c - m e t + stem cells,
and mononuclear cells expressing early cardiac, muscle, and
endothelial markers into peripheral blood in patients with
acute myocardial infarction,” Circulation, vol. 110, no. 20, pp.
3213–3220, 2004.
[5] G. P. Fadini, L. Pucci, R. Vanacore et al., “Glucose tolerance
is negatively associated with circulating progenitor cell levels,”
Diabetologia, vol. 50, no. 10, pp. 2156–2163, 2007.
[6] G. P. Fadini, S. Sartore, M. Albiero et al., “Number and
function of endothelial progenitor cells as a marker of severity
for diabetic vasculopathy,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 26, no. 9, pp. 2140–2146, 2006.
[7] T. Q. Nguyen, H. Chon, F. A. Van Nieuwenhoven, B.
Braam, M. C. Verhaar, and R. Goldschmeding, “Myoﬁbroblast
progenitor cells are increased in number in patients with type
1 diabetes and express less bone morphogenetic protein 6: a
novel clue to adverse tissue remodelling?” Diabetologia, vol.
49, no. 5, pp. 1039–1048, 2006.
[8] G.P.FadiniandM.Tjwa,“AroleforTGF-betaintransforming
endothelial progenitor cells into neointimal smooth muscle
cells,” Atherosclerosis, vol. 211, no. 1, pp. 32–35, 2010.Experimental Diabetes Research 7
[9] C.J .M.Loomans,R.V anHaperen,J .M.Duijsetal.,“Diﬀeren-
tiation of bone marrow-derived endothelial progenitor cells is
shifted into a proinﬂammatory phenotype by hyperglycemia,”
Molecular Medicine, vol. 15, no. 5-6, pp. 152–159, 2009.
[10] G.P.Fadini,C.Agostini,S.Sartore,andA.Avogaro,“Endothe-
lial progenitor cells in the natural history of atherosclerosis,”
Atherosclerosis, vol. 194, no. 1, pp. 46–54, 2007.
[11] G. P. Fadini, S. Sartore, C. Agostini, and A. Avogaro, “Signiﬁ-
cance ofendothelialprogenitorcells insubjectswithdiabetes,”
Diabetes Care, vol. 30, no. 5, pp. 1305–1313, 2007.
[12] R. C. Johnson, J. A. Leopold, and J. Loscalzo, “Vascular calci-
ﬁcation: pathobiological mechanisms and clinical implica-
tions,” Circulation Research, vol. 99, no. 10, pp. 1044–1059,
2006.
[13] M. Abedin, Y. Tintut, and L. L. Demer, “Vascular calciﬁca-
tion: mechanisms and clinical ramiﬁcations,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 24, no. 7, pp. 1161–
1170, 2004.
[14] G. Z. Eghbali-Fatourechi, J. Lamsam, D. Fraser, D. Nagel, B.
L. Riggs, and S. Khosla, “Circulating osteoblast-lineage cells in
humans,” New England Journal of Medicine, vol. 352, no. 19,
pp. 1959–1966, 2005.
[15] G. P. Fadini, M. Albiero, L. Menegazzo et al., “Widespread
increase in myeloid calcifying cells contributes to ectopic
vascular calciﬁcation in type 2 diabetes,” Circulation Research,
vol. 108, no. 9, pp. 1112–1121, 2011.
[16] K. P. Egan, J.-H. Kim, E. R. Mohler, and R. J. Pignolo, “Role
forcirculating osteogenic precursor cells in aorticvalvular dis-
ease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
31, no. 12, pp. 2965–2971, 2011.
[17] J. Wylie-Sears, E. Aikawa, R. A. Levine, J.-H. Yang, and
J. Bischoﬀ, “Mitral valve endothelial cells with osteogenic
diﬀerentiation potential,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 31, no. 3, pp. 598–607, 2011.
[18] J.R.Gavin, K.G. M.M.Alberti,M.B.Davidson et al.,“Report
of the expert committee on the diagnosis and classiﬁcation of
diabetes mellitus,” Diabetes Care, vol. 26, supplement 1, pp.
S5–S20, 2003.
[19] “Classiﬁcation of diabetic retinopathy from ﬂuorescein angio-
grams. ETDRS report number 11. Early Treatment Diabetic
Retinopathy Study Research Group,” Ophthalmology, vol. 98,
pp. 807–822, 1991.
[20] A. S. Levey, L. A. Stevens, C. H. Schmid et al., “A new equa-
tion to estimate glomerular ﬁltration rate,” Annals of Internal
Medicine, vol. 150, no. 9, pp. 604–612, 2009.
[21] G.P.Fadini,S.Sartore,I.Baessoetal.,“Endothelialprogenitor
cells and the diabetic paradox,” Diabetes Care, vol. 29, no. 3,
pp. 714–716, 2006.
[22] G. P. Fadini, S. De Kreutzenberg, M. Albiero et al., “Gender
diﬀerences in endothelial progenitor cells and cardiovascular
risk proﬁle: the role of female estrogens,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 28, no. 5, pp. 997–1004,
2008.
[23] E. Chavakis, A. Hain, M. Vinci et al., “High-mobility group
box 1 activates integrin-dependent homing of endothelial
progenitorcells,” CirculationResearch,vol.100,no.2,pp.204–
212, 2007.
[24] T. Asahara, H. Masuda, T. Takahashi et al., “Bone marrow
origin of endothelial progenitor cells responsible for postnatal
vasculogenesis in physiological and pathological neovascular-
ization,”CirculationResearch,vol.85,no.3,pp.221–228,1999.
[25] G. P. Fadini, I. Baesso, M. Albiero, S. Sartore, C. Agostini, and
A. Avogaro, “Technical notes on endothelial progenitor cells:
ways to escape from the knowledge plateau,” Atherosclerosis,
vol. 197, no. 2, pp. 496–503, 2008.
[26] M. G¨ o s s l ,U .I .M¨ odder, R. Gulati et al., “Coronary endothelial
dysfunction in humans is associated with coronary retention
of osteogenic endothelial progenitor cells,” European Heart
Journal, vol. 31, no. 23, pp. 2909–2914, 2010.
[27] M. G¨ o s s l ,U .I .M ¨ odder, E. J. Atkinson, A. Lerman, and
S. Khosla, “Osteocalcin expression by circulating endothelial
progenitor cells in patients with coronary atherosclerosis,”
Journal of the American College of Cardiology, vol. 52, no. 16,
pp. 1314–1325, 2008.
[28] E. Chavakis, A. Aicher, C. Heeschen et al., “Role of β2-inte-
grins for homing and neovascularization capacity of endothe-
lial progenitor cells,” Journal of Experimental Medicine, vol.
201, no. 1, pp. 63–72, 2005.
[29] A. Aicher, W. Brenner, M. Zuhayra et al., “Assessment of the
tissue distribution of transplanted human endothelial pro-
genitor cells by radioactive labeling,” Circulation, vol. 107, no.
16, pp. 2134–2139, 2003.
[30] W. J. Jeﬀcoate, L. M. Rasmussen, L. C. Hofbauer, and F. L.
Game, “Medial arterial calciﬁcation in diabetes and its rela-
tionship to neuropathy,” Diabetologia, vol. 52, no. 12, pp.
2478–2488, 2009.
[31] J. He, Z. Xiao, X. Chen et al., “The expression of functional
toll-like receptor 4 is associated with proliferation and main-
tenance of stem cell phenotype in endothelial progenitor cells
(EPCs),” Journal of Cellular Biochemistry, vol. 111, no. 1, pp.
179–186, 2010.
[32] P. Romagnani, F. Annunziato, F. Liotta et al., “CD14+CD34low
cells with stem cell phenotypic and functional features are
the major source of circulating endothelial progenitors,” Cir-
culation Research, vol. 97, no. 4, pp. 314–322, 2005.
[33] D. T. Graves and R. A. Kayal, “Diabetic complications and dy-
sregulated innate immunity,” Frontiers in Bioscience, vol. 13,
no. 4, pp. 1227–1239, 2008.
[34] B. Guillotin, R. Bareille, C. Bourget, L. Bordenave, and J.
Am´ ed´ ee, “Interaction between human umbilical vein endo-
thelial cells and human osteoprogenitors triggers pleiotropic
eﬀect that may support osteoblastic function,” Bone, vol. 42,
no. 6, pp. 1080–1091, 2008.
[35] L. Liu, Z.-Z. Liu, H. Chen, G.-J. Zhang, Y.-H. Kong, and X.-
X. Kang, “Oxidized low-density lipoprotein and β-glycero-
phosphate synergistically induce endothelial progenitor cell
ossiﬁcation,” Acta Pharmacologica Sinica, vol. 32, no. 12, pp.
1491–1497, 2011.